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Bn ,dients with a myocardial infarction, coronary 
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nar, artery and the onset of myocardial infarction (1). 
Resolution of the coronary thrmbus is the aim of ireatment 
with thrambolytic agents (2). Since the introduction of 
tkrombolytic Fhempy for suspected acute myocardial infarc- 
tion, the evidence for the benefit d his treatment has been 
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4 91% to 99% diameter stenosis, no complete filling within 3 cycles 
5 Total occlusim with or without cdlateral filtim 
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formed to determine r occlusion. 
tams were an i~d~~~t~~~ for the
formed earlier. In case of ~~~~~~~y a 
rut, 
intention to treat principle, 
Power calculations for the therapeutic groups were made. 
These data are reported in detail in B recen 
that provides the clinical data from the 
Because the expected reoccllusisn rate aft 
unknown, adequate calculation of statistical power For the 
detection of differences between the two categories of ste- 
nosis everity was not possible. 
On behalf of the Scientific Council of the Interuniversity 
Cardiology Institute of the Netherlands, an external r;Rnical 
epidemiologist ~~Qrrned interim analysis on the basis of the 
intention to treat principle after 100 and 2 
protocJ changes were indicated. 
Three hundred patients were included in the APRICOT 
study. Retrospectively, the angiography committee x- 
ieats because the infarct-r 
(1 receiving ~o~mad~~, 5 
11 (5%) underwent coronary bypass 
coumadin, 8 placebo). On clinical indi- 
cations and after ecur~~t myocardial infarction, 5.5 patients 
underwent repeat a~~~~g~ 
protocol. In 31 (56%) 
found. 
c Characteris- 
ts with iaargio- 
graphic follow-up are listed in Table 2. There were no 
significant diITerences in age, time delay in start of throm- 
bolysis and timing of angiography among the diEerent treat- 
are shown in Table 3 
the first and second an 
the placebo group (p = 
Reocclusion rate increased with culprit lesion ~tmxh se- 
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1153 37 23 
72 30 42* 
108 24 23 
140 47 34t 
*p < 0.01, NJ% versus -SOS. tp < 0.05, smooth versus complex. 
at the end of the 
m which reocclu- 
sion was shown to be relate e clinical outcome 
(e.g., recurrent ischernia and 
ieft ventricular function). The study of Ohman et al, (16) also 
is an adverse vent. 
Studies reporting reoe- 
treatment regimen (8,20,28,2 
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stenosis severity did not 
large scale study reported here, in which reocclusion was a 
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r&tics of rhe culgrit lesion just 
fore planned elective ~~~~~~y 
mbolysis were described by 
They could not identify 
recurrent ischemia or 
practice, where ~uant~ficatio~~ is timeconsuming, ~rn~r~ct~~ 
cd and cumbersome. and 
s in 
fmc selection and n can give rise to 
aracterization f a stenosis (39). 
Recent studies demonstrate that 
coronary angioplasty foroptimal patient care is not indicated 
without ischemic signs after thrombolysis (15,21). In our 
study, angioplasty was not intended, and therefore the 
ration between the cul 
lysis and reacelusion 
y planed invasiv previously described 
simple angiographic features ofthe culprit lesion are easy to 
obtain doing routine angiography without automated quan- 
titative analysis and strongly predict reocclusion after SW 
cessful thrombolysis. 
Because r occlusion significantly interferes with left ven- 
tricular function (16), it should be prevented by all means. In 
a recent publication (24) from the APRICOT trial it was 
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